Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Thomas, D.; McDonald, V.M.; Pavord, I.D.; Gibson, P.G. Asthma Remission—What Is It and How Can It Be Achieved? Eur. Respir. J. 2022, 60, 2102583. [Google Scholar] [CrossRef] [PubMed]
- Eger, K.; Kroes, J.A.; ten Brinke, A.; Bel, E.H. Long-Term Therapy Response to Anti–IL-5 Biologics in Severe Asthma—A Real-Life Evaluation. J. Allergy Clin. Immunol. Pract. 2021, 9, 1194–1200. [Google Scholar] [CrossRef] [PubMed]
- Kavanagh, J.E.; d’Ancona, G.; Elstad, M.; Green, L.; Fernandes, M.; Thomson, L.; Roxas, C.; Dhariwal, J.; Nanzer, A.M.; Kent, B.D.; et al. Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma. Chest 2020, 158, 491–500. [Google Scholar] [CrossRef] [PubMed]
- Kavanagh, J.E.; Hearn, A.P.; Dhariwal, J.; d’Ancona, G.; Douiri, A.; Roxas, C.; Fernandes, M.; Green, L.; Thomson, L.; Nanzer, A.M.; et al. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest 2021, 159, 496–506. [Google Scholar] [CrossRef] [PubMed]
- Nakajima, M.; Matsuyama, M.; Arai, N.; Yamada, H.; Hyodo, K.; Nonaka, M.; Kitazawa, H.; Yoshida, K.; Shigemasa, R.; Morishima, Y.; et al. Identification of Whole Blood Gene Expressions Correlated with Responsiveness to Benralizumab. J. Allergy Clin. Immunol. 2021, 147, 772–775. [Google Scholar] [CrossRef] [PubMed]
- Menzies-Gow, A.; Hoyte, F.L.; Price, D.B.; Cohen, D.; Barker, P.; Kreindler, J.; Jison, M.; Brooks, C.L.; Papeleu, P.; Katial, R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv. Ther. 2022, 39, 2065–2084. [Google Scholar] [CrossRef] [PubMed]
- Numata, T.; Araya, J.; Okuda, K.; Miyagawa, H.; Minagawa, S.; Ishikawa, T.; Hara, H.; Kuwano, K. Long-Term Efficacy and Clinical Remission after Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study. J. Asthma Allergy 2022, 15, 1731–1741. [Google Scholar] [CrossRef] [PubMed]
- Maglio, A.; Vitale, C.; Pelaia, C.; D’Amato, M.; Ciampo, L.; Sferra, E.; Molino, A.; Pelaia, G.; Vatrella, A. Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study. Int. J. Mol. Sci. 2023, 24, 2455. [Google Scholar] [CrossRef] [PubMed]
- Nagase, H.; Suzukawa, M.; Oishi, K.; Matsunaga, K. Biologics for Severe Asthma: The Real-World Evidence, Effectiveness of Switching, and Prediction Factors for the Efficacy. Allergol. Int. 2023, 72, 11–23. [Google Scholar] [CrossRef] [PubMed]
- GINA. Global Strategy for Asthma Management and Prevention. 2023. Available online: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf (accessed on 20 May 2023).
- Harada, N.; Ito, J.; Takahashi, K. Clinical effects and immune modulation of biologics in asthma. Respir Investig. 2021, 59, 389–396. [Google Scholar] [CrossRef] [PubMed]
- Sposato, B.; Scalese, M.; Milanese, M.; Masieri, S.; Cavaliere, C.; Latorre, M.; Scichilone, N.; Ricci, A.; Cresti, A.; Santus, P.; et al. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes. J. Allergy Clin. Immunol. Pract. 2019, 7, 1643–1646. [Google Scholar] [CrossRef] [PubMed]
- Matucci, A.; Vivarelli, E.; Bormioli, S.; Francesca, N.; Chiccoli, F.; Valentina, M.; Francesca, G.; Oliviero, R.; Parronchi, P.; Vultaggio, A. Long-Term Retention Rate of Mepolizumab Treatment in Severe Asthma: A 36-Months Real-Life Experience. J. Asthma 2023, 60, 158–166. [Google Scholar] [CrossRef]
- Menigoz, C.; Dirou, S.; Chambellan, A.; Hassoun, D.; Moui, A.; Magnan, A.; Blanc, F.X. Use of FeNO to Predict Anti-IL-5 and IL-5R Biologics Efficacy in a Real-World Cohort of Adults with Severe Eosinophilic Asthma. J. Asthma 2022, 60, 1162–1170. [Google Scholar] [CrossRef] [PubMed]
OMALIZUMAB | MEPOLIZUMAB | BENRALIZUMAB | DUPILUMAB | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AR (66–21.8%) | Non AR (236–78.2%) | p | AR (13–23.6%) | Non AR (42–76.4%) | p | AR (34–35.8%) | Non AR (61–64.2%) | p | AR (8–23.5%) | Non AR (26–76.5%) | p | |
Age | 48.4 ± 11.7 | 53.9 ± 13.4 | 0.001 | 57.1 ± 13.5 | 56.9 ± 13.7 | 0.996 | 55.9 ± 11.2 | 59.2 ± 12.6 | 0.165 | 58.3 ± 12.2 | 59.8 ± 12.7 | 0.439 |
Sex (M/F) | 27/39 | 77/159 | 0.210 | 6/7 | 17/25 | 0.716 | 13/21 | 23/38 | 0.959 | 2/6 | 12/14 | 0.514 |
Treatment time | 37.8 ± 19.2 | 37.9 ± 19.4 | 0.992 | 13.5 ± 1.7 | 14.4 ± 2.6 | 0.322 | 15.4 ± 5.5 | 20.4 ± 7.3 | 0.010 | 12 ± 0 | 13 ± 0.96 | 0.017 |
Smokers | 19 (28.8%) | 51 (21.6%) | 0.221 | 0 (0%) | 3 (7.1%) | 0.770 | 2 (5.9%) | 3 (4.9%) | 0.781 | 0 (0%) | 0 (0%) | --- |
BMI | 25.9 ± 4.8 | 27.1 ± 4.7 | 0.054 | 24.6 ± 2.38 | 26.1 ± 4.1 | 0.239 | 25.5 ± 4.1 | 27 ± 4.1 | 0.059 | 25.5 ± 2.1 | 27.5 ± 3.7 | 0.486 |
Obese subjects | 10 (15.1%) | 56 (23.7%) | 0.136 | 0 (0%) | 8 (19.0%) | 0.210 | 5 (14.7%) | 13 (21.3%) | 0.430 | 0 (0%) | 4 (15.4%) | 0.579 |
Age of asthma onset | 24.8 ± 15.8 | 29.9 ± 17.4 | 0.026 | 43.7 ± 14.6 | 36.1 ± 16.5 | 0.109 | 35.1 ± 14.4 | 36.6 ± 14.6 | 0.623 | 32.7 ± 15.7 | 35.5 ± 19.6 | 0.810 |
House dust mite | 54 (81.8%) | 205 (86.9%) | 0.299 | 5 (38.4%) | 15 (35.7%) | 0.857 | 11 (32.3%) | 18 (29.5%) | 0.773 | 1 (12.5%) | 13 (50%) | 0.140 |
Pollens | 43 (65.1%) | 148 (62.7%) | 0.716 | 1 (7.7%) | 16 (38.1%) | 0.083 | 11 (32.3%) | 21 (34.4%) | 0.837 | 2 (25%) | 14 (53.8%) | 0.305 |
Cat/dog dander | 22 (33.3%) | 70 (29.7%) | 0.566 | 1 (7.7%) | 5 (11.9%) | 0.933 | 5 (14.7%) | 6 (9.8%) | 0.477 | 0 (0%) | 4 (15.4%) | 0.579 |
Moulds | 9 (13.6%) | 43 (18.2%) | 0.383 | 4 (30.7%) | 1 (2.4%) | 0.010 | 1 (2.9%) | 5 (8.2%) | 0.569 | 0 (0%) | 3 (11.5%) | 0.769 |
Rhinitis | 42 (63.6%) | 161 (68.2%) | 0.483 | 8 (61.5%) | 24 (57.1%) | 0.778 | 21 (61.8%) | 25 (41%) | 0.052 | 5 (62.5%) | 20 (76.9%) | 0.726 |
Sinusitis/polyposis | 17 (25.7%) | 116 (49.2%) | 0.001 | 8 (61.5%) | 29 (69) | 0.614 | 22 (64.7%) | 30 (49.2%) | 0.145 | 5 (62.5%) | 18 (69.2% | 0.939 |
Hypertension | 14 (21.2%) | 90 (38.1%) | 0.010 | 2 (15.4%) | 13 (31%) | 0.456 | 4 (11.8%) | 16 (26.2%) | 0.163 | 0 (0%) | 5 (19.2%) | 0.439 |
Chronic heart disease | 1 (1.5%) | 37 (15.7%) | 0.004 | 0 (0%) | 2 (4.7%) | 0.963 | 2 (5.9%) | 4 (6.6%) | 0.756 | 0 (0%) | 1 (3.8%) | 0.526 |
Diabetes | 3 (4.5%) | 17 (7.2%) | 0.625 | 1 (7.7%) | 3 (7.1%) | 0.586 | 1 (2.9%) | 3 (4.9%) | 0.942 | 0 (0%) | 0 (0%) | --- |
Osteoporosis | 5 (7.6%) | 26 (11%) | 0.415 | 1 (7.7%) | 9 (21.4%) | 0.477 | 1 (2.9%) | 7 (11.5%) | 0.293 | 2 (25%) | 4 (15.4%) | 0.925 |
Gastro-esophageal reflux | 19 (28.8%) | 90 (38.1%) | 0.162 | 3 (23.1%) | 16 (38.1%) | 0.508 | 10 (29.4%) | 23 (37.7%) | 0.415 | 2 (25%) | 5 (19.2%) | 0.883 |
OSAS | 3 (4.5%) | 7 (3%) | 0.806 | 0 (0%) | 1 (2.4%) | 0.531 | 0 | 5 (8.2%) | 0.216 | 0 (0%) | 0 (0%) | --- |
Mental disorders | 3 (4.5%) | 27 (11.4%) | 0.154 | 4 (30.7%) | 14 (33.3%) | 0.868 | 8 (23.5%) | 21 (34.4%) | 0.268 | 0 (0%) | 3 (11.5%) | 0.769 |
Exacerbations | 2.62 ± 1.25 | 3.13 ± 1.41 | 0.007 | 3.31 ± 1 | 4.5 ± 2.1 | 0.037 | 4.6 ± 2.7 | 3.8 ± 2.1 | 0.156 | 4 ± 0.9 | 4.5 ± 2.4 | 0.890 |
ACT | 15.9 ± 4.7 | 14.9 ± 5.1 | 0.439 | 15.7 ± 4.6 | 13.3 ± 3.7 | 0.052 | 15.2 ± 4.3 | 15.7 ± 4.3 | 0.464 | 14.6 ± 1.4 | 14.7 ± 2.2 | 0.897 |
FEV1 % | 72.1 ± 15.6 | 69.5 ± 19.9 | 0.121 | 83.4 ± 10.1 | 67.7 ± 19.1 | 0.005 | 73.7 ± 22.5 | 75.1 ± 26.8 | 0.854 | 76.1 ± 14.5 | 65.2 ± 20.3 | 0.183 |
FEF25–75% | 42.3 ± 23.6 | 40.1 ± 19.8 | 0.786 | 46.4 ± 13.7 | 28.7 ± 20 | 0.006 | 44.2 ± 20.8 | 50 ± 27.8 | 0.478 | 33.3 ± 8.7 | 34.7 ± 12.9 | 0.506 |
Total serum IgE UI/ml | 374.8 ± 292.2 | 385.6 ± 319.2 | 0.797 | 275 ± 298.5 | 373.2 ± 647.4 | 0.971 | 440.3 ± 729.6 | 459.3 ± 739.0 | 0.829 | 119.7 ± 72 | 364 ± 481 | 0.081 |
Blood eosinophils (n/µL) | 314.5 ± 271 | 357.5 ± 288.7 | 0.457 | 574 ± 329 | 839.8 ± 1054 | 0.407 | 993.5 ± 728 | 808.6 ± 689.4 | 0.112 | 500 ± 158.4 | 607 ± 328.9 | 0.661 |
FENO (ppb) | 36.4 ± 32.3 | 35 ± 40.2 | 0.752 | 76.2 ± 50.7 | 41.3 ± 22.3 | 0.050 | 51.5 ± 31.5 | 45.9 ± 36.4 | 0.376 | 53.7 ± 5.1 | 54.1 ± 15.6 | 0.904 |
Continuous oral corticosteroids use (pre-treatment) | 7 (10.6%) | 33 (18.2%) | 0.474 | 10 (76.9%) | 35 (83.3%) | 0.911 | 19 (55.6%) | 37 (60.7%) | 0.650 | 4 (50%) | 17 (65.4%) | 0.713 |
Subjects with a previous treatment with other biologics | - | - | 2 (15.4%) | 8 (19%) | 0.910 | 5 (14.7%) | 14 (23%) | 0.335 | 4 (50%) | 12 (46.1%) | 0.830 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sposato, B.; Bianchi, F.; Ricci, A.; Scalese, M. Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics. J. Pers. Med. 2023, 13, 1020. https://doi.org/10.3390/jpm13061020
Sposato B, Bianchi F, Ricci A, Scalese M. Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics. Journal of Personalized Medicine. 2023; 13(6):1020. https://doi.org/10.3390/jpm13061020
Chicago/Turabian StyleSposato, Bruno, Francesco Bianchi, Alberto Ricci, and Marco Scalese. 2023. "Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics" Journal of Personalized Medicine 13, no. 6: 1020. https://doi.org/10.3390/jpm13061020